ReviewFrontiers in oncology2024

Homologous recombination proficient subtypes of high-grade serous ovarian cancer: treatment options for a poor prognosis group.

Nadja Stiegeler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.